Compare PSMT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSMT | TGTX |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.9B |
| IPO Year | 2005 | 2008 |
| Metric | PSMT | TGTX |
|---|---|---|
| Price | $159.33 | $41.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.80 |
| AVG Volume (30 Days) | 221.5K | ★ 1.9M |
| Earning Date | 04-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | 5.47 | ★ 1746.67 |
| EPS | ★ 2.91 | 2.77 |
| Revenue | ★ $4,066,093,000.00 | $2,785,000.00 |
| Revenue This Year | $12.29 | $49.08 |
| Revenue Next Year | $10.70 | $26.69 |
| P/E Ratio | $54.66 | ★ $15.10 |
| Revenue Growth | ★ 12.33 | N/A |
| 52 Week Low | $99.98 | $25.37 |
| 52 Week High | $165.46 | $42.09 |
| Indicator | PSMT | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 74.20 |
| Support Level | $140.50 | $26.93 |
| Resistance Level | $165.35 | N/A |
| Average True Range (ATR) | 4.75 | 1.77 |
| MACD | -0.50 | 0.22 |
| Stochastic Oscillator | 49.05 | 98.08 |
Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.